https://www.selleckchem.com/products/SNS-032.html
798). Moreover, there was no significant difference in either the overall survival benefit (hazard ratio [HR] = 0.84, 95% confidence interval [CI] 0.49-1.45, P = 0.532) or disease-free survival rate (HR = 0.95, 95% CI 0.52-1.75, P = 0.864). CONCLUSIONS The evidence obtained does not support PCI therapy in the management of surgically resected SCLC with no lymph node involvement. KEY POINTS Prophylactic cranial irradiation (PCI) remains controversial for resected small-cell lung cancer (SCLC) without lymph node involvement. In this study
Aimer
Commentaire
Partagez
